SCHEMBL12029432

SCHEMBL12029432

O=C(Nc1nccs1)c1cccc2c(=O)cc(-c3cccc(OC(F)F)c3)[nH]c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ RAB9A P51151 4/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ TAAR1 Q96RJ0 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ CSNK2A2 P19784 1/20 0.42
▸ CSNK2B P67870 1/20 0.42
▸ CSNK2A1 P68400 1/20 0.42
▸ CSNK2A3 Q8NEV1 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ NPC1 O15118 4/20 0.41
▸ GAA P10253 2/20 0.41
▸ MGAM O43451 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12029433 0.90 LMNA (0.43) HPGDLMNAMAPTRAB9ASMN1; SMN2
SCHEMBL12029435 0.88 CSNK2A2 (0.46) HPGDLMNAMAPTRAB9ASMN1; SMN2
SCHEMBL12029440 0.85 ALOX15 (0.46) HPGDLMNAMAPTRAB9ASMN1; SMN2
SCHEMBL12029436 0.84 MGAM (0.52) HPGDLMNAMAPTRAB9AALDH1A1
SCHEMBL12029397 0.84 LMNA (0.45) HPGDLMNAMAPTRAB9ASMN1; SMN2
SCHEMBL12029454 0.81 KMT2A (0.47) HPGDLMNAMAPTRAB9ASMN1; SMN2
SCHEMBL12029439 0.80 CSNK2A2 (0.46) HPGDLMNAMAPTRAB9ASMN1; SMN2
SCHEMBL12029430 0.77 MEN1 (0.53) HPGDLMNAMAPTRAB9ASMN1; SMN2
SCHEMBL12029431 0.77 CSNK2A2 (0.46) HPGDLMNAMAPTRAB9ASMN1; SMN2
SCHEMBL12029434 0.77 ALOX15 (0.46) HPGDLMNAMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9326986-B2 Quinazolinone, quinolone and related analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2016-05-03 — — US disclosed
US-9326986-B2 Quinazolinone, quinolone and related analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2016-05-03 — — US disclosed
US-20110306612-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-12-15 — — US disclosed
US-20110306612-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-12-15 — — US disclosed
WO-2010037129-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS INC. (US) 2010-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306612-A1 QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 HPGD 207/4885LMNA 2930/4885MAPT 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback